Capstone Investment Advisors
RARE icon

Capstone Investment Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Capstone Investment Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$331K Buy
+15,797
New +$356K ﹤0.01% 1324
2024
Q4 		– Sell
-13,089
Closed -$727K – 1983
2024
Q3 		$727K Buy
+13,089
New +$667K ﹤0.01% 1087
2024
Q2 		– Sell
-4,863
Closed -$227K – 2392
2024
Q1 		$227K Buy
+4,863
New +$229K ﹤0.01% 1962

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capstone Investment Advisors's RARE Position: Q1 2026 in Review

Capstone Investment Advisors opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 15,797 shares worth $331K. The stake represents ﹤0.01% of the portfolio and ranks #1324 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in RARE as recently as Q3 2024.

Capstone Investment Advisors first reported a position in RARE in Q1 2024 and has held it in 3 quarters since. The position peaked at $727K in Q3 2024. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Capstone Investment Advisors held 15,797 shares of Ultragenyx Pharmaceutical worth $331K as of Q1 2026.
  • Ultragenyx Pharmaceutical was a new Capstone Investment Advisors position in Q1 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #1324 holding.
  • Capstone Investment Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and has held it in 3 quarters since.
  • Capstone Investment Advisors's Ultragenyx Pharmaceutical position peaked at $727K in Q3 2024.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.